Table 1 Patient characteristics at diagnosis, recurrence (treated by fSRT), 3 months after fSRT, and recurrence after fSRT
From: Pattern of recurrence after fractionated stereotactic reirradiation in adult glioblastoma
At diagnosis | |
Age (years) | 59 (38–78) |
Female | 28 (45.2) |
Surgical procedure | |
- Gross total resection | 15 (24.2) |
- Subtotal resection | 29 (46.8) |
- Biopsy | 18 (29) |
Adjuvant systemic therapy | |
- Temozolomide | 50 (80.6) |
- Bevacizumab | 1 (1.6) |
- Nivolumab | 1 (1.6) |
- Temozolomide + Bevacizumab | 7 (11.3) |
- Temozolomide + Nivolumab | 1 (1.6) |
- Temozolomide ± Pazopanib | 1 (1.6) |
- None | 1 (1.6) |
Subventricular zone invasion | |
- Yes | 10 (16.1) |
- No | 52 (83.9) |
At fSRT recurrence | |
Age (years) | 60 (40–78) |
KPS (%) | |
- ≥ 70 | 59 (95.2) |
- < 70 | 3 (4.8) |
Number of previous recurrences/treatments | |
- 0 | 53 (85.5) |
- 1 | 8 (12.9) |
- Fotemustine + Bevacizumab | 2 (3.2) |
- Lomustine + Bevacizumab | 1 (1.6) |
- Surgery + radiochemotherapy with Temozolomide | 1 (1.6) |
- Temozolomide | 3 (4.8) |
- Surgery | 1 (1.6) |
- 2 | 1 (1.6) |
- Temozolomide then Fotemustine + Bevacizumab | 1 (1.6) |
Systemic therapy | |
- Yes | 27 (43.5) |
- Fotemustine + Bevacizumab | 4 (6.5) |
- Temozolomide + Bevacizumab | 2 (3.2) |
- Belustine + Bevacizumab | 1 (1.6) |
- Bevacizumab | 4 (6.5) |
- Temozolomide | 14 (22.6) |
- Muphoran | 1 (1.6) |
- Lomustine | 1 (1.6) |
- No | 35 (56.5) |
Multifocality | |
- Yes | 12 (19.4) |
- No | 50 (80.6) |
Steroids | |
- Yes | 18 (29) |
- No | 44 (71) |
Toxicity | |
- None | 46 (74.2) |
- Grade 1 | 12 (19.4) |
- Grade 2 | 3 (4.8) |
- Grade 3 | 1 (1.6) |
At 3 months after fSRT | |
KPS (%) | |
- ≥ 70 | 50 (80.6) |
- < 70 | 12 (19.4) |
Steroids | |
- Yes | 35 (56.5) |
- No | 26 (41.9) |
At recurrence (after fSRT) | |
KPS (%) | |
- ≥ 70 | 43 (69.4) |
- < 70 | 19 (30.6) |